We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ligand Pharmaceuticals Inc. (LGND - Free Report) reported third-quarter 2017 adjusted earnings of 69 cents per share, significantly up 56.8% from the year-ago figure of 44 cents. The bottom line also beat the Zacks Consensus Estimate of 60 cents.
Ligand’s shares have outperformed the industry year to date. The stock has soared 42.5% compared with the industry’s 2.7% increase.
Total revenues in the quarter surged 54.6% year over year to $33.4 million, mainly on the back of higher royalty revenues. The top line also surpassed the Zacks Consensus Estimate of $31 million.
Quarterly Highlights
Royalty revenues were $21.9 million in the reported quarter, up approximately 39.5% year over year. Higher royalties on sales of Novartis' (NVS - Free Report) Promacta, Amgen's (AMGN - Free Report) Kyprolis and Spectrum Pharmaceuticals' Evomela drove this upside. Ligand licenses its platform technologies such as Captisol or OmniAb to partners for use in their proprietary programs.
Material sales also soared by 83.3% to $7.7 million owing to the favorable timing of Captisol purchases for clinical and commercial use.
License and milestone revenues were $3.8 million, registering a massive rise of 123.5% compared with $1.7 million in the year-ago period. This increase was courtesy of the favorable timing of milestones and license fees earned.
Research & development (R&D) expenses marginally decreased by 18.6% to $4.8 million. However, general & administrative expenses increased 6.1% year over year to $7 million.
Pipeline and Other Updates
In September, Ligand Pharmaceuticals announced positive top-line results from a phase II study, evaluating the efficacy and safety of its pipeline candidate LGD-6972, for treatment of patients with type 2 diabetes mellitus (T2DM), inadequately controlled on metformin monotherapy. The study achieved statistical significance in the primary endpoint of change from baseline in hemoglobin A1c after 12 weeks of treatment at all doses (5 mg, 10 mg and 15 mg) tested.
In July, the company announced that it has entered into a commercial license and supply agreement with Amgen, granting it rights to use Captisol in the formulation of its anti-CD33 x anti-CD3 (BiTE) bi-specific antibody, AMG 330. Under the terms of the deal, Ligand is entitled to potential milestone payments, royalties and revenues from the future sales of AMG 330.
2017 Outlook
Ligand raised its 2017 earnings and revenue outlook. The company now expects revenues in the range of $134-$136 million compared with the previous expectation of at least $134 million along with up to $9 million as contract payments.
Adjusted earnings are now expected in the range of $2.95-$3.00 per share compared with the past projection of $2.93.
Ligand Pharmaceuticals Price, Consensus and EPS Surprise
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised
Ligand Pharmaceuticals Inc. (LGND - Free Report) reported third-quarter 2017 adjusted earnings of 69 cents per share, significantly up 56.8% from the year-ago figure of 44 cents. The bottom line also beat the Zacks Consensus Estimate of 60 cents.
Ligand’s shares have outperformed the industry year to date. The stock has soared 42.5% compared with the industry’s 2.7% increase.
Total revenues in the quarter surged 54.6% year over year to $33.4 million, mainly on the back of higher royalty revenues. The top line also surpassed the Zacks Consensus Estimate of $31 million.
Quarterly Highlights
Royalty revenues were $21.9 million in the reported quarter, up approximately 39.5% year over year. Higher royalties on sales of Novartis' (NVS - Free Report) Promacta, Amgen's (AMGN - Free Report) Kyprolis and Spectrum Pharmaceuticals' Evomela drove this upside. Ligand licenses its platform technologies such as Captisol or OmniAb to partners for use in their proprietary programs.
Material sales also soared by 83.3% to $7.7 million owing to the favorable timing of Captisol purchases for clinical and commercial use.
License and milestone revenues were $3.8 million, registering a massive rise of 123.5% compared with $1.7 million in the year-ago period. This increase was courtesy of the favorable timing of milestones and license fees earned.
Research & development (R&D) expenses marginally decreased by 18.6% to $4.8 million. However, general & administrative expenses increased 6.1% year over year to $7 million.
Pipeline and Other Updates
In September, Ligand Pharmaceuticals announced positive top-line results from a phase II study, evaluating the efficacy and safety of its pipeline candidate LGD-6972, for treatment of patients with type 2 diabetes mellitus (T2DM), inadequately controlled on metformin monotherapy. The study achieved statistical significance in the primary endpoint of change from baseline in hemoglobin A1c after 12 weeks of treatment at all doses (5 mg, 10 mg and 15 mg) tested.
In July, the company announced that it has entered into a commercial license and supply agreement with Amgen, granting it rights to use Captisol in the formulation of its anti-CD33 x anti-CD3 (BiTE) bi-specific antibody, AMG 330. Under the terms of the deal, Ligand is entitled to potential milestone payments, royalties and revenues from the future sales of AMG 330.
2017 Outlook
Ligand raised its 2017 earnings and revenue outlook. The company now expects revenues in the range of $134-$136 million compared with the previous expectation of at least $134 million along with up to $9 million as contract payments.
Adjusted earnings are now expected in the range of $2.95-$3.00 per share compared with the past projection of $2.93.
Ligand Pharmaceuticals Price, Consensus and EPS Surprise
Ligand Pharmaceuticals Incorporated Price, Consensus and EPS Surprise | Ligand Pharmaceuticals Incorporated Quote
Zacks Rank
Ligand carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>